The Impact On Carers Is Routinely Ignored In Value For Money Assessments

Published Sep 17, 2012
Birmingham, UK - With rising health care costs, value for money assessments play an important role in determining which health care interventions are provided. Value for money assessments should consider the resources used in the intervention and the full health impact of that intervention. This normally includes considering hard-to-measure costs and benefits for carers. A recent study "The inclusion of informal care in applied economic evaluation: a review," published in Value in Health, investigates whether value for money assessments are considering the costs and benefits of health care interventions on carers. The authors found that very few assessments considered carer costs or outcomes, but those that did showed carer impact played an important role in determining whether an intervention was good value for money. The study was co-authored by Kacey Goodrich, Billingsley Kaambwa and Hareth Al-Janabi at the University of Birmingham. Dr. Al-Janabi says "Practice is lagging behind theory when it comes to including the impacts on carers in health economic evaluations. Our review suggests value for money assessments can be highly sensitive to the impacts on carers and so we would urge researchers to consider these impacts in their evaluations, either in the main analysis, or in a sensitivity analysis."

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision-makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Launches New Content on Whole Health

Sep 23, 2025

ISPOR announced that it has launched new website content on whole health, a topic of increasing importance as health systems across the globe grapple with providing the best possible healthcare to patients within constrained budgets.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×